Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)

Inclusion Criteria * Male or female age ≥21 years. * Asian race (e.g. Chinese, Japanese, Korean, Thai). * Polypoidal choroidal vasculopathy in the study eye * Presence of ≥ 1 visible polypoidal varicosity on ICGA. * Presence of a measurable branching vascular network * BCVA by ETDRS of 68 to 4 letters in the study eye. Ophthalmologic Exclusion Criteria * Prior treatment with intravitreal or systemic anti-VEGF therapy within 60 days of enrollment. * Any other prior treatment for PCV including thermal laser photocoagulation, photodynamic therapy (i.e., verteporfin), or any investigational therapies. * Any history of prior retinal or subretinal surgery, transpupillary thermography, radiation, implantation of intravitreal drug delivery device, vitrectomy. * Any other intraocular surgery or laser treatment within 90 days or any surgeries planned during the study period. * Fibrosis involving ≥50% of the total lesion. * Presence of hemorrhage which potentially obscures \>75% of vascular pathology to be assessed by imaging procedures. * Retinal or choroidal vascular disease in study eye due to causes other than PCV, such as uveitis, trauma, or pathologic myopia. * Macular edema in either eye due to other causes, such as diabetic retinopathy. * Evidence of glaucomatous eye disease, glaucomatous visual field loss. * History of allergy to fluorescein or ICG dye. Medical Exclusion Criteria * Current or history within two years of any significant heart disease. * Uncontrolled hypertension.